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Abstract 
Background: Both pulmonary tuberculosis (PTB) and diabetes mellitus (DM) are major global public health prob-
lems. We estimated the global, regional, and national prevalence of diabetes mellitus in a population with PTB.
Methods: We searched for observational studies of DM in people with PTB using the PubMed and Embase electronic 
bibliographic databases, focusing on articles published in the English language from database inception until March 
31, 2021. We included original research that reported the prevalence of DM in PTB or those that had sufficient data to 
compute these estimates. Studies were excluded if they did not provide primary data or were case studies or reviews. 
Two authors independently extracted the articles and collected detailed information using a predefined question-
naire. A country-specific random-effects meta-analysis was used for countries with two or more available studies, and 
a fractional response regression model was employed to predict the prevalence of DM in PTB for countries with one 
or no study. The study was registered with the International Prospective Register of Systematic Reviews, using the 
registration number CRD42018101989.
Results: We identified 22,658 studies, and 153, across 51 countries, were retained for data extraction. The global 
prevalence of DM among patients with PTB was estimated to be 13.73% (95% confidence interval [CI] 12.51–14.95). 
The prevalence rates were 19.32% (95% CI 13.18–25.46) in the region of the Americas, 17.31% (95% CI 12.48–22.14) in 
the European region, 14.62% (95% CI 12.05–17.18) in Southeast Asia, 13.59% (95% CI 7.24–19.95) in the western Pacific 
region, 9.61% (95% CI 4.55–14.68) in the eastern Mediterranean region, and 9.30% (95% CI 2.83–15.76) in the African 
region. The country with the highest estimated prevalence was the Marshall Islands (50.12%; 95% CI 4.28–95.76).
Conclusion: Comorbid PTB and DM remain prevalent worldwide.
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Background
Both tuberculosis (TB) and diabetes mellitus (DM) are 
major global public health problems. Despite laudable 
progress policies and medical care in the control of TB, 
the World Health Organization (WHO) reported 10 mil-
lion cases of TB and 1.3  million TB-related deaths in 
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increasing in recent decades [2]; as of 2015, more than 
415 million adults had DM, and this number is estimated 
to increase to 642 million by 2040 [3].
Since the early part of the twentieth century, clinicians 
have observed an association between DM and TB in 
what has been described as a co-epidemic [4–7]. Previ-
ous research has shown that the risk of developing DM 
is threefold higher in people with TB than in those with-
out, suggesting that the TB epidemic is fueling the DM 
epidemic [8]. According to another systematic review, 
DM has a major effect on TB treatment outcomes in 
that patients with TB and DM are at greater combined 
risk of treatment failure, relapse, and death than those 
without [9]. Considering the dual burden of these two 
diseases, the WHO and the International Union Against 
Tuberculosis and Lung Disease (“the Union”) launched a 
collaborative framework, which emphasizes the need to 
establish a collaborative mechanism between National 
Tuberculosis Programs and diabetes organizations and to 
expand the bi-directional screening of TB and DM [10].
Pulmonary TB (PTB) presents in the lung, which is the 
major target organ in 85% of cases [11]. An increasing 
number of studies have demonstrated that patients with 
PTB are also screened for DM [12–21]. The global bur-
den of DM among patients with TB has been estimated 
before [22]; however, the global prevalence of DM among 
patients with PTB, the most common form of TB, has not 
been fully determined. Therefore, we performed a sys-
tematic review and meta-analysis to estimate the global, 
regional, and national prevalence of DM (any type) in 
patients with PTB. We expect our results to provide the 
most up-to-date information on the national, regional, 
and global rates of DM among patients with PTB.
Methods
Protocol and registration
This review follows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines [23]. The full review protocol is available in 
the International Prospective Register of Systematic 
Reviews (PROSPERO), with the registration number 
CRD42018101989.
Eligibility criteria
Cross-sectional studies, cohort studies, and those with 
monitoring data reporting the number/prevalence of DM 
among patients with PTB were included. We also con-
sidered case–control studies in which patients with PTB 
comprised the case group and that reported the preva-
lence or number of patients with DM in the case group. 
Participants of eligible studies were required to have a 
diagnosis of PTB.
Information sources
Studies were identified by searching the PubMed and 
Embase literature databases. The search for relevant arti-
cles was limited to those that were written in English, 
included only human beings, and were published from 
database inception until March 31, 2021.
Literature search
We developed a comprehensive systematic literature 
search method to standardize the screening of arti-
cles and identify all studies reporting the prevalence or 
number of cases of DM among patients with PTB in any 
country. A detailed description of the main keywords 
used for the search strategy is available in Additional 
file 1: Table S1 and Box S1, P2 and P3.
Study selection
Two reviewers (M. M. L. and Z. Q. H.) independently 
selected studies for inclusion. First, the two review-
ers excluded any articles that did not meet the inclu-
sion criteria by screening titles and abstracts. Then, both 
reviewers read the full texts of the remaining articles. 
During the full-text screening, the reference lists were 
also reviewed to identify any additional relevant studies. 
Lastly, the reviewers extracted the relevant data from the 
included articles. If the full text of an article could not be 
found, we attempted to contact the corresponding author 
of the article to obtain the full text using the information 
provided in the abstract. Disagreements were resolved by 
team discussions about the articles retained and the data 
extracted.
Data‑collection process
We designed a customized questionnaire (Additional 
file 1: Questionnaire P5) and EpidData database for data 
extraction. The extracted data included the following: 
article title, publication time, study design, number of 
patients with PTB, and number or prevalence of patients 
with DM among the total PTB cases. Two authors (M. 
M. L. and Z. Q. H.) independently extracted the relevant 
information and input it into the EpidData version 3.1 
software program (EpiData Association, Odense, Den-
mark). Meanwhile, we collected data on TB incidence, 
gross domestic product (GDP), human development 
index (HDI), and human capital index (HCI) from the 
World Bank Open Data website [24].
Data items
The following information was extracted from each 
included article: (1) article title, (2) publication time, (3) 
study design, (4) study country, (5) study time, (6) age 
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range, (6) number of patients with PTB, (7) number/
prevalence of patients with PTB and DM. See Additional 
file 1: Questionnaire P4.
Risk of bias in individual studies
The quality of each included study was assessed using a 
modified version of a critical appraisal tool designed for 
use in systematic reviews addressing questions of preva-
lence [25]. Two reviewers (M. M. L. and Z. Q. H.) inde-
pendently assessed the studies, and any disagreement 
was resolved through consensus.
Summary measures
Global, regional, and national rates of DM and PTB were 
the primary measures. The meta-analyses were per-
formed by computing the prevalence rate using a ran-
dom-effects model and multilevel fractional response 
regression modeling, and 95% confidence interval (CI) 
values were calculated using the Monte Carlo method.
Planned methods of analysis
A country-specific random-effects meta-analysis method 
was used to estimate the pooled prevalence of DM among 
patients with PTB for countries with two or more empiri-
cal studies. Before performing the meta-analysis, the 
prevalence of DM among patients with PTB reported in 
each study was transformed using a double arcsine trans-
formation. For countries with one or no empirical stud-
ies, we predicted the country’s prevalence of DM among 
patients with PTB using multilevel fractional response 
regression modeling. In detail, we generalized a linear 
model with a binomial family and a logit link to restrict 
final predictions ranging from 0 to 1. The following pre-
dictor variables were added in the fractional response 
regression model to predict the prevalence of comorbid 
PTB and DM: no predictor variables (model 1); study 
years and GDP in the study years (or nearest years if the 
GDP was unavailable in the study years) (model 2); and 
study years, GDP in the study years (or nearest years if 
GDP was unavailable in the study years), HDI for the year 
2020, and HCI for the year 2020 (model 3). Data on the 
GDP, HDI, and HCI were acquired from the World Bank 
Open Data website. The standard error for each coun-
try estimate was based on the variation between studies 
included in the meta-analysis.
To estimate the prevalence of DM in PTB among the 
six WHO regions and globally, we calculated a weighted 
average of the prevalence of DM among patients with 
PTB weighted by the predicted number of patients with 
TB in each country for the last year with data avail-
able (2019). To estimate the 95% CI values of these 
point estimates, we used the Monte Carlo method 
(drawing 1,000,000 samples per country) to generate 
the corresponding 1,000,000 weighted averages of the 
regions and globally. The normal distribution assumption 
of the average was used to estimate the 95% CI values.
The I2 statistic was used to assess the heterogeneity 
[26]. We considered I2 values of 25% to 49% as indicative 
of low heterogeneity, 50% to 74% as indicative of moder-
ate heterogeneity, and at least 75% as indicative of high 
heterogeneity, respectively [27]. All analyses were per-
formed using Stata version 15.0 (StataCorp LLC, College 
Station, TX, USA) [28].
Risk of bias across studies
We used Egger’s test to detect publication bias [14]. A 
P-value of less than 0.10 on Egger’s test was considered 
indicative of statistically significant publication bias. It 
was decided a priori that, if publication bias were present, 
it would not be adjusted for, given that it was assumed 
that the prevalence estimates of interest would likely be 




The search of the PubMed and Embase databases pro-
vided a total of 22,658 citations. After adjusting for dupli-
cates, 16,690 remained. Of these, 16,171 studies were 
further discarded after their abstracts were read because 
it appeared that these papers clearly did not meet the 
criteria, and the full texts of the remaining 519 citations 
were examined in greater detail; at this point, it appeared 
that another 366 studies did not meet the inclusion cri-
teria as described. Finally, a total of 153 studies were 
Fig. 1 Flow chart of literature search for studies on the prevalence of 
DM in patients with PTB
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identified for inclusion in the present review. No unpub-
lished relevant studies were obtained (Fig. 1).
Study characteristics
All 153 articles finally selected for this review were obser-
vational studies published in the English language before 
March 31, 2021. The included studies contained 983,552 
patients with PTB, including 138,474 with DM, across 51 
countries. Data were available for 17 studies involving 13 
countries in the African region; 15 studies involving six 
countries in the eastern Mediterranean region; 12 studies 
involving nine countries in the European region; 33 stud-
ies involving seven countries in the region of the Ameri-
cas; 40 studies involving eight countries in the Southeast 
Asian region; and 39 studies involving eight countries 
in the western Pacific region. Twenty countries had two 
or more studies, and the three countries with the most 
studies were China (n = 22), India (n = 20), and Mexico 
(n = 9).
Results of individual studies
The prevalence of DM among patients with PTB in the 
included articles is shown in Additional file 1: Table S2.
Risk of bias within studies
The critical appraisal of included studies and a complete 
reference list of all included studies are shown in Addi-
tional file 1: Table S3.
Syntheses of results
The prevalence of DM among patients with PTB was esti-
mated for 184 countries (via a meta-analysis for 20 coun-
tries [with two or more available empirical studies] and 
via statistical modeling [prediction] for 164 countries). 
The prevalence of DM among patients with PTB could 
not be estimated for 11 countries because of missing 
data for one or more predictor variables. The final model 
included the following predictor variables: GDP (β = 0.01 
[referring to an increase of 100,000 international dol-
lars]; 95% CI − 0.01 to 0.01), HDI (β = 0.24 [referring to 
a 10% increase]; 95% CI − 0.96 to 1.43), TB incidence 
(β =  − 0.01 [referring to a 1% increase]; 95% CI − 0.01 
to 0.01), and DM prevalence (β = 0.09 [referring to a 1% 
increase]; 95% CI − 0.14 to 0.31).
The five countries with the highest estimated preva-
lence of DM among patients with PTB were the Marshall 
Islands (50.12%; 95% CI 4.28–95.76), Mauritius (41.59%; 
95% CI 4.02–92.38), Nauru (40.89%; 95% CI 1.80–96.31), 
the United Arab Emirates (36.42%; 95% CI 5.07–79.31), 
and Bahrain (32.81%; 95% CI 5.86–79.32). The five coun-
tries with the lowest prevalence of DM among patients 
with PTB were Lesotho (3.90%; 95% CI 0.04–782.06), 
Mozambique (4.01%; 95% CI 0.07–72.62), Liberia (4.36%; 
95% CI 0.18–52.57), Sierra Leone (4.43%; 95% CI 0.21–
50.39), and the Central African Republic (4.53%; 95% CI 
0.09–70.93). The prevalence of DM among patients with 
PTB by country is illustrated in Fig.  2 and Additional 
file 1: Table S4. The results of the tests of heterogeneity 
and publication bias for the meta-analysis of the preva-
lence of DM among patients with PTB by country are 
shown in Additional file 1: Table S5.
The global prevalence of DM among patients with PTB 
was estimated to be 13.73% (95% CI 12.51–14.95). The 
highest prevalence of DM among patients with PTB was 
in the region of the Americas (19.32%; 95% CI 13.18–
25.46), and the lowest prevalence of DM among patients 
with PTB was in the African region (9.30%; 95% CI 
2.83–15.76). Additionally, the prevalence of DM among 
patients with PTB was 17.31% (95% CI 12.48–22.14) in 
the European region, 14.62% (95% CI 12.05–17.18) in 
the Southeast Asian region, 13.59% (95% CI 7.24–19.95) 
in the western Pacific region, and 9.61% (95% CI 4.55–
14.68) in the eastern Mediterranean region (Table 1).
Discussion
Summary of evidence
In the present study, we estimated the global, regional, 
and national prevalence rates of DM among patients with 
PTB for the first time. Although the prevalence of PTB 
appears to be decreasing overall, comorbid PTB and DM 
remain prevalent in several countries. First, we found that 
the global predicted prevalence of DM among patients 
with PTB was 13.73% (95% CI 12.51–14.95). Addition-
ally, the prevalence among individual regions ranged 
from 9.30% (95% CI 2.83–15.76) in the African region to 
19.32% (95% CI 13.18–25.46) in the region of the Ameri-
cas, and the prevalence among countries ranged from 
3.90% (95% CI 0.04–82.06) in Lesotho to 50.12% (95% CI 
4.28–95.76) in the Marshall Islands.
Differences in prevalence rates
Compared with the global prevalence, the prevalence of 
DM in patients with PTB was higher in the region of the 
Americas, the European region, and the Southeast Asia 
region, while the African region had the lowest preva-
lence of comorbid PTB and DM. This may be linked 
to the fact that countries in the region of the Americas 
have experienced the fastest increase in DM prevalence 
along with a high burden of TB and human immunodefi-
ciency virus [29, 30]. The European region also showed a 
high prevalence of DM among patients with PTB, which 
can be attributed to effective infection disease preven-
tion and better-resourced health systems [31]. India 
has the highest number of TB cases (27%) in the world 
and a very high burden of DM, even within the South-
east Asian region [32]. The African region has the lowest 
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prevalence of DM, which could be explained by the lack 
of some DM risk factors, including prevalence of excess 
weight and obesity, aging of the population, and hyper-
tension [18]. In addition, most PTB and DM cases in 
African regions are not registered at the local depart-
ment, and the majority of facilities are still not screening 
for DM among patients with PTB, partly due to cost and 
perceived complexities. Furthermore, there is a lack of 
treatment infrastructure for those who do screen posi-
tive, which can lead to underdiagnosis of DM, which may 
also explain the underprevalence of DM among patients 
with PTB in the African region [33–36].
The five countries with the highest estimated preva-
lence of comorbid PTB and DM were the Marshall 
Islands, Mauritius, Nauru, the United Arab Emirates, and 
Bahrain. The five countries with the lowest prevalence 
of comorbid PTB and DM were Lesotho, Mozambique, 
Liberia, Sierra Leone, and the Central African Republic. 
Sociodemographic factors (sex, age, and income), behav-
ioral attributes (tobacco smoking and alcohol drinking), 
and clinical and other factors are also associated with 
comorbid TB and DM [1]. The differences in prevalence 
rates of these conditions between countries can also be 
explained by variations in the risk factors of comorbid 
PTB and DM.
Sensitivity analyses revealed high heterogeneity in 
Brazil. Several factors may have contributed to this het-
erogeneity, including the sampling methodology, study 
subjects, study year(s), geographical location, variabil-
ity within the specific subpopulation studied, sex and 
age-group representation in the population sample, and 
Fig. 2 Global prevalence of PTB combined DM. A multilevel fractional response regression modeling (for countries with one or no empirical 
studies) and country-specific random- effects meta-analysis methods (for countries with two or more empirical studies) were used to predict the 
country’s prevalence of DM in PTB patients
Table 1 The global prevalence (%) of DM in patients with PTB, 
by country and WHO region
95% CI were calculated by using the Monte Carlo method
WHO world health organization
WHO Region Prevalence (%) 95% confidence 
interval
Lower Upper
African Region 9.30 2.83 15.76
Eastern Mediterranean Region 9.61 4.55 14.68
European Region 17.31 12.48 22.14
Region of the Americas 19.32 13.18 25.46
South-East Asia region 14.62 12.05 17.18
Western Pacific Region 13.59 7.24 19.95
Globally 13.73 12.51 14.95
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publication bias. However, it was not possible to quan-
tify the contribution of these sources of variation to the 
heterogeneity in the association through a meta-regres-
sion analysis given the relatively small number of studies 
available.
Numerous studies have presented convincing biologi-
cal evidence in support of the causal relationship between 
DM and impaired host immunity to TB. Indeed, several 
recent animal models of Mycobacterium tuberculosis 
have demonstrated an unexpected development of DM, 
particularly in those treated with anti-glycemic therapy 
as host-directed therapy for TB [37]. Thus, PTB may 
identify individuals at higher risk of progression to DM. 
Another possible mechanism by which PTB may increase 
the risk of DM is through changes in body composition 
during and following the illness. Patients with PTB fre-
quently lose a substantial amount of weight before and 
in the early stages of treatment. Limited evidence from 
cohort studies suggests that the regaining of weight dur-
ing treatment could increase the proportion of body fat 
in recovered patients with TB, which may increase their 
future risk of DM [38, 39].
Public health recommendations
Given the high prevalence of comorbid PTB and DM and 
its adverse outcomes, we strongly believe that greater 
investments are needed to reduce the prevalence of 
comorbid PTB and DM. There are several recommen-
dations to facilitate such improvements: for the Depart-
ment of Public Health, conduct early bi-directional DM 
screening for patients with PTB, especially in the African 
region, as well as improving collection and monitoring 
of data for PTB and DM; for clinical medicine organi-
zations, focus on developing and implementing clinical 
guidelines and tools to improve the management and 
care of individuals with PTB at risk of DM; and, for the 
medical research institutions, perform further studies to 
understand whether DM causes PTB or vice versa so that 
this combination can be better predicted and prevented.
Limitations
There are several potential limitations to this study. First, 
we did not include studies published in all languages, 
which may have resulted in some relevant studies being 
excluded. However, as high-quality studies tend to be 
published in English, we do not consider this to have had 
a significant impact on our findings. Second, we included 
studies that did not consistently define the diagnosis of 
PTB and DM, with different criteria being used in differ-
ent countries. However, the diagnosis of both PTB and 
DM in most of the countries references the WHO stand-
ards. Third, the predicted prevalence estimates for the 
168 countries with either one or no available study might 
diverge from the actual prevalence because the data from 
which the values were predicted carry some measure-
ment error. In addition, other relevant explanatory varia-
bles, which may not be possible to account for, may affect 
the prevalence of DM with PTB. However, taking into 
consideration this study and the fact that we were limited 
to the information reported in the included studies, we 
consider the present model to have yielded the best esti-
mates. Finally, it should also be noted that this study was 
limited to WHO member states.
Conclusions
In conclusion, comorbid PTB and DM is a crucial global 
health issue that must be addressed to reduce adverse 
treatment outcomes and mortality globally and improve 
patients’ quality of life. Our findings suggest that early 
standardized bi-directional screening of DM in patients 
with TB and screening of TB in patients with DM should 
be implemented as soon as possible. DM control pro-
grams should also consider targeting patients with PTB 
for interventions, such as active case finding and the 
treatment of hyperglycemia. Efforts to diagnose, detect, 
and treat PTB may have a beneficial impact on DM con-
trol. To better understand the global epidemiology of DM 
among patients with PTB, the quality and volume of data 
need to be strengthened, including standardizing defini-
tions, measurement, monitoring, and reporting. Further 
research on the causes of comorbid PTB and DM and 
new interventions to prevent and manage the conse-
quences of comorbid PTB and DM (particularly in low- 
and middle-income regions) are also needed.
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